Last year, Reckitt Benckiser agreed to pay $700 million to settle a six qui tam lawsuit filed by Pennsylvania and other states in connection with its improper marketing of Suboxone Sublingual Tablet.
Indivior settles FTC complaint that it blocked generic competition to Suboxone
